Disclosures Infective Endocarditis: 2016 Update I have nothing to - - PDF document

disclosures
SMART_READER_LITE
LIVE PREVIEW

Disclosures Infective Endocarditis: 2016 Update I have nothing to - - PDF document

12/17/16 Disclosures Infective Endocarditis: 2016 Update I have nothing to disclose Ann Bolger, MD William Watt Kerr Professor of Medicine Incidence of IE: Shifts and Controversies in IE Patient Age and Organism Populations at risk


slide-1
SLIDE 1

12/17/16 1

Infective Endocarditis: 2016 Update Ann Bolger, MD William Watt Kerr Professor of Medicine

Disclosures

I have nothing to disclose

Shifts and Controversies in IE

Populations at risk

Increasing patient age and comorbidity Increasing prevalence of health care-associated infection Illicit drug use

More virulence

  • S. aureus rather than streptococcal species

Other organisms: Group B strep, Bartonella Antibiotic resistance

Increasing rate of surgical intervention during initial hospitalization New imaging approaches to diagnosis Prophylaxis guidelines

Competing policies from international societies Trends and costs relating to prophylaxis strategies

Hoen B, Duval X. Infective Endocarditis. N Engl J Med 2013.

Incidence of IE:

Patient Age and Organism

slide-2
SLIDE 2

12/17/16 2

Device-related Endocarditis

Bor DH, et al. (2013) Infective Endocarditis in the U.S., 1998–2009: A Nationwide Study. PLoS ONE 8(3), 2014

Healthcare-Associated IE

Seven-hospital cohort study in Spain 795 consecutive IE cases 16% Health care-associated infection

  • lder patients

more co-morbid conditions more staphylococcal infections (58% vs 25% in community-acquired infection) Main cause: Vascular access (venous catheter infection in 30%) In-hospital mortality of Healthcare associated infection was 45% (vs 24% in community-acquired, P<0.001)

Lomas JM, et al. Healthcare-associated infective endocarditis: an undesirable effect of healthcare universalization. Clin Microbiol Infect 2010.

Patient: 57 year old male with ESRD/HD

CC: Fatigue and malaise for 6 weeks No dyspnea or fever No intolerance of HD Outpatient workup: Urine culture: S. viridans Blood cultures at dialysis: MSSA Vancomycin begun at HD Sent for outpatient echocardiogram

slide-3
SLIDE 3

12/17/16 3

Patient course:

No CHF or evidence of embolization Blood cultures negative Hemodialysis catheter replaced CT for detection of embolization followed by pulmonary edema; rapid improvement with hemodialysis

Could we have prevented this infection? How should we manage it?

The Burden of IE in Hemodialysis Patients

400,000 patients on RRT in the US in 2009 6-8% increase per year IE is second leading cause of mortality Incidence 308/100,000 patient-years: 50-fold higher than general population

Werdan K et al. Mechanisms of infective endocarditis: pathogen–host interaction and risk states. Nat Rev Cardiol 2013 Jones DA, et al. Characteristics and outcomes of dialysis patients with infective endocarditis. Nephron Clin Pract 2013 Rate of IE per 1000 patients

slide-4
SLIDE 4

12/17/16 4

The Burden of IE in Hemodialysis Patients

Jones DA, et al. Characteristics and outcomes of dialysis patients with infective endocarditis. Nephron Clin Pract 2013

Mortality approximately 50% (47 - 66%) Mostly Staphylococcal Mostly left-sided Frequent heart failure and embolism Poor prognostic factors Age >60 years Septic emboli MRSA

TAVR vs SAVR: Early endocarditis

Amat-Santos IJ et al. Prosthetic valve endocarditis after transcatheter valve replacement JACC: Cardiovascular Interventions 8:2015 Amat-Santos IJ et al. Prosthetic valve endocarditis after transcatheter valve replacement JACC: Cardiovascular Interventions 8:2015

Time from TAVR or TPVR to Infective Endocarditis

230 million people (1 in 20) around the world used illicit drugs in 2011 27 million (0.6%) of the world’s adult population are “problem drug users” Mostly heroin and cocaine dependent Methamphetamine Prescription opiates are expanding rapidly

http://www.guardian.co.uk/news/datablog/interactive/2012/jul/02/d rug-use-map-world

UN Office on Drugs and Crime: World Drugs Report 2012

slide-5
SLIDE 5

12/17/16 5

Heroin source dictates distribution, and type predicts practice Colombia Eastern US Mexico Western US Southeast Asia Australia and Canada Afghanistan/Pakistan Europe Black tar heroin (Mexico): Heavier, distributed by land. Vaporizable but acidic and irritating. Requires heat to dissolve. More venous scarring; SQ or IM routes have lower HIV transmission. More soft tissue infections, botulism and clostridial infections. White heroin (Southeast Asia): Lighter, water soluble and vaporizable. HIV prevalence higher with powder heroin.

Ciccarone D. Heroin in brown, black and white: Structural factors and medical consequences in the US heroin market. International Journal of Drug Policy 2009 (20).

Heroin in Brown, Black and White Influence of Drug of Choice on IE Characteristics

Jain V et al. Infective endocarditis in an urban medical center: association

  • f individual drugs with valvular involvement. J Infect (57) 2008

Retrospective cohort of 247 cases of IE 74% cases in IDU, most with heroin

  • S. aureus IE was most prevalent and more

likely to occur in IDUs versus non-IDUs (OR 5.5, p<0.0001). Tricuspid valve (TV) IE was more likely to

  • ccur in IDUs (OR 4.37, p=0.001)

TV IE occurred more frequently in heroin users vs. IDUs not using heroin (OR 4.03, p=0.033) Heroin use may underlie the association between IDU and right-sided endocarditis.

Chirouze C, et al. Infective endocarditis prophylaxis: moving from dental prophylaxis to global prevention? Eur J Clin Microbiol Infect Dis 2012

The next controversy? IE prevention in the current context

French population-based surveys in 1991, 1999, 2008

slide-6
SLIDE 6

12/17/16 6

Gaca JG, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J Thorac Cardiovasc Surg 2011

Predictors of Operative Mortality

Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database, 2002 through 2008 19,543 IE operations Operative mortality: 8.2% Nearly half of patients did not have active IE at the time of surgery

Independent predictors of mortality:

Urgency of surgery Hemodynamic status Renal failure Active infection Multiple valve involvement Diabetes mellitus Arrhythmia Previous cardiac surgery

Prospective cohort study of 1552 patients with native valve IE Surgery in 46% during index hospitalization In-hospital mortality of early surgery vs medical therapy: 12.1% vs 20.7% (P<0.001) Absolute risk reduction: -5.9% (after propensity-based matching and adjustment for survivor bias)

Lalani T, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment selection bias. Circulation, 2010

Impact of Early Surgery on Mortality

(International Collaboration of Endocarditis)

Heart failure Intracardiac abscess Embolic events Severe valvular regurgitation Failure of antibiotic therapy

Conventional surgical indications:

In-hospital mortality (%) Quintile of surgical likelihood No surgery Surgery

Stroke in Endocarditis

Stroke occurs in Left-sided IE in 20-40% 5% are intracranial hemorrhage Mycotic aneurysm forms in 2-4% of patients with IE 50% resolve with therapy Mortality in un-ruptured is 30%, ruptured 80% 95% are embolic 70% of emboli occur in the first 15 days after diagnosis Mortality 58% Asymptomatic emboli can be detected in 30% of aortic or mitral IE

slide-7
SLIDE 7

12/17/16 7

Influence of Stroke on Surgical Timing

Risk of neurological deterioration in case of symptomatic brain infarction (small, retrospective series) < 4 days: 20% 4-14 days: 20–50% 15-28 days: <10% >28 days: <1%

Conclusion: Surgery should be considered within the first 72 h if a patient with stroke has severe CHF, otherwise after 4 wks

Angstworm K, et al. J Neuro 2004

Multicenter prospective study of 496 consecutive IE patients Cerebrovascular complications in 22% of patients Neurological exacerbation in 6.3% (only in patients with symptomatic CVA) No excess surgical mortality with silent CVC or TIA

Conclusion: Safe to proceed to valve replacement despite transient ischemic attacks or ‘‘silent’’ cerebral embolism

Thuny F, et al. Eur Heart J 2007

Current Guidelines: Stroke and Surgery for Endocarditis

Amat-Santos IJ et al. Prosthetic valve endocarditis after transcatheter valve replacement JACC: Cardiovascular Interventions 8:2015

“Timing of surgery in patients with symptomatic ischemic stroke should be a balance of the severity of cardia decompensation and pathology and the severity

  • f the neurological symptoms.

Patients with severe cardiac decompensation and severe mechanical cardiac lesions should be operated on emergently or urgently unless the neurological status (eg coma, large intracranial hemorrhage) precludes heparinization or when neurological recovery to reasonable quality of life is very unlikely (eg, multiple strokes or severe neurological deficits in patients with preexisting comorbidities. For patients with IE and parenchymal hemorrhage, it is reasonable to proceed for small lesions or to delay surgery, typically between 0 and 4 weeks, depending

  • n the size of involvement and the urgency of the operations.”

Amat-Santos IJ et al. Prosthetic valve endocarditis after transcatheter valve replacement JACC: Cardiovascular Interventions 8:2015

Stroke and Surgery for Endocarditis in TAVR

CT

Cerebral

All patients at admission to detect cerebral infarction, hemorrhage, aneurysms

Abdominal

Uncontrolled infection or difficult situations, to detect visceral infarction, abscess or aneurysm

MRI

Cerebral

Better sensitivity for small cerebral infarctions and hemorrhages without radiation or contrast

Angiography

Cerebral

In patients with hemorrhage, suspicion of aneurysm with negative CT or MRI, or aneurysm detected on CT or MRI

PET/CT

Suspicion of prosthetic valve or pacemaker lead endocarditis with negative echo

Thuny F, et al. Imaging investigations in infective endocarditis: Current approach and perspectives. Arch Cardiovascular Dis, 2013

Beyond Echo: Imaging in IE

slide-8
SLIDE 8

12/17/16 8

PET/CT in IED Endocarditis

n Site Sensitivity Specificity Bensimhon 21 Pocket + Leads 80 100 Leads 60 100 Ploux 10 Leads 100 93 Sarrazin 42 Pocket + Leads 89 86

Thuny F, et al. Imaging investigations in infective endocarditis: Current approach and perspectives. Arch Cardiovascular Dis 2013 Bensimhon L et al. Whole body [18F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect 2011 Ploux S et al. Positron emission tomography in patients with suspected pacing system infections may play a critical role in difficult

  • cases. Heart Rhythm 2011

Sarrazin JF et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 2012 Thuny F, et al. Management of infective endocarditis: challenges and perspectives. Lancet 2012

CT PET Fused PET/CT

PET/CT in Endocarditis

Thuny F, et al. Imaging investigations in infective endocarditis: Current approach and perspectives. Archives of Cardiovascular Disease 2013

Day 1 Day 2 Day 8

The mission of IE prophylaxis…

… to avoid endocarditis by targeting predictable bacteremias with organisms that can cause endocarditis in patients with more than baseline risk

  • f infection

Does prophylaxis decrease bacteremia? Does prophylaxis avoid IE? Do the benefits of prophylaxis outweigh the risks?

slide-9
SLIDE 9

12/17/16 9

The mission of IE prophylaxis…

… to avoid endocarditis by targeting predictable bacteremias with organisms that can cause endocarditis in patients with more than baseline risk

  • f infection

Does prophylaxis decrease bacteremia? Does prophylaxis avoid IE? Do the benefits of prophylaxis outweigh the risks?

2007 Recommendations: Focus on Patients at risk

Focus shift from lifetime IE risk defined by natural history of specific predisposing cardiac conditions, to patients with the highest risk of the worst IE outcomes:

Prosthetic Cardiac Valves Previous Bacterial Endocarditis Complex Cyanotic Congenital Heart Disease, with surgically constructed systemic-pulmonary shunts or conduits Transplant recipients with valvular insufficiency

International recommendations

*2002 French guidelines †2006 British Society for Antimicrobial Chemotherapy ‡2007 American Heart Association

# procedures recommended for prophylaxis

Duval X, Leport C. Lancet Infect Dis 2008

Time …National Institute for Health and Clinical Excellence (NICE) in 2008: “No indication for antibiotic prophylaxis against IE”

Thornhill MH, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ 2011

Prophylaxis prescriptions

Is the sky falling? The UK experience

NICE

IE Cases

NICE

slide-10
SLIDE 10

12/17/16 10

Follow up of NICE Guidelines:

Thornhill MH, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ 2011

Follow of 2007 AHA Guidelines:

DeSimone DC, et al. Incidence of Infective Endocarditis Caused by Viridans Group Streptococci Before and After Publication of the 2007 American Heart Association’s Endocarditis Prevention Guidelines. Circulation 2012 Pasquali SK, et al. Trends in endocarditis hospitalization at US children’s hospital: Impact

  • f the 2007 American Heart Association antibiotic prophylaxis guidelines. Am Heart J 2012

Follow up of 2002 French Guidelines:

Duval X, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications. J Am Coll Card 2012

Is the sky falling?

US Population-based survey 1999 through 2010

DeSimone DC, et al. Incidence of Infective Endocarditis Caused by Viridans Group Streptococci Before and After Publication of the 2007 American Heart Association’s Endocarditis Prevention Guidelines. Circulation 2012

Incidence

2000 4000 6000 8000 10000 12000 14000 16000 18000 20000 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Years Total number of discharges

Inpatient Sample Database

~8 million hospital admissions/year ~20% of stratified sample of US community hospitals Adults >18 yrs 1999 - 2010

Pasquali SK, et al. Trends in endocarditis hospitalization at US children’s hospital: Impact of the 2007 American Heart Association antibiotic prophylaxis guidelines. Am Heart J 2012 Bates KE, et al. Cardiol Young 2016

Pediatric Health Information Systems Database

37 centers, 2003-2010 1157 IE cases 68% had CHD 48% <1 year old

Results

Trend (P=0.05) toward decrease over time

Follow up of 2007 Guidelines in 2012: Pediatrics

Franklin M, et al. The cost-effectiveness of antibiotic prophylaxis for patients at risk of infective

  • endocarditis. Circulation 134, 2016

Notes increase in cases of IE since 2008; no bacteriology In High-Risk individuals, prophylaxis is cost-effective if it only prevents 1.44 cases of IE per year Propose that using prophylaxis in those high risk patients would save 4 million pounds and >1070 QALYs per year in England Extending it to moderate risk patients could save up to 8.2 million pounds and >2600 QALYs

IE Prophylaxis in the UK: Cost effective?

slide-11
SLIDE 11

12/17/16 11

What to watch for

Ongoing revisions of professional society guidelines Additional shifts in bacteriology New patient groups at risk New strategies for neuro protection to permit earlier surgery Increasing use of multimodality imaging for detection and treatment planning in IE